Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rMBCG in NMIBC
NCT06800963Phase 2Recruiting
- Sponsor
- ImmunityBio, Inc.
- Start
- Oct 2025
- Primary completion
- Feb 2028
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of recombinant BCG in non-muscle-invasive bladder cancer (NMIBC), sponsored by ImmunityBio, Inc. Primary endpoint: Adverse Events at 7 months. Started Oct 2025; status: recruiting.
02
Drugs
recombinant BCG
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT06800963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06800963.